Global Pericardiocentesis Procedures Market By Type (Therapeutic Procedure, Diagnostic Procedure); By Technique (Fluoroscopy-guided Technique, Ultrasound- guided Technique, Computed Tomography- guided Technique, Others); By Disease Indication (Infections (Viral (including HIV), Bacterial, Mycobacterial, Fungal and Protozoal), Infection of the Heart or Pericardial Sac, Surgery or Invasive Heart Procedures, Chest Trauma, Malignancy (Lung, Breast, Lymphoma, Melanoma, Others), Immune System Disease, Reactions to certain drugs, Radiation, Kidney (renal) Failure, Others); By Healthcare Setting (Hospitals and Clinics, Cardiac Centers, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
Pericardiocentesis is a medical procedure used to diagnose and treat a variety of heart-related conditions. During this procedure, a long thin catheter is inserted through the chest wall and into the pericardial sac around the heart. This allows fluid or air to be removed from the area, providing diagnostic information about any underlying heart issues. In some cases, it can also be used for therapeutic purposes such as reducing fluid build-up around the heart or removing blood clots. Pericardiocentesis procedures are relatively low risk and have become increasingly popular in recent years due to their ability to provide a wealth of diagnostic information. They are becoming increasingly popular across the globe as a safe and reliable method of diagnosing and treating a number of heart-related conditions. In recent years, the number of these procedures performed in the US, Europe and Asia has grown exponentially with more and more medical professionals seeing their value in accurately diagnosing and treating various cardiac illnesses. In addition, technological advancements such as minimally invasive catheters that enable treatments to be carried out without open-heart surgery have made this type of procedure even safer for patients. As a result, pericardiocentesis procedures are being used more often for both diagnostic and therapeutic purposes, which is propelling the demand of the pericardiocentesis procedures market globally.
In terms of revenue, global pericardiocentesis procedures market was valued at US$ 2.3 Bn in 2022 and is projected to reach CAGR of 8.1% over the forecast period (2023 – 2031). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Type Outlook
On the basis of type, the of global pericardiocentesis procedures market is further categorized into therapeutic procedure and diagnostic procedure. When used for diagnostic purposes, a catheter is inserted through the chest wall and into the pericardial sac around the heart, allowing fluid or air to be removed from the area. This helps to provide information about any underlying heart issues and can aid in diagnosing a range of conditions including congestive heart failure, pericarditis, ventricular tachycardia, and cardiac tamponade. When used for therapeutic purposes, a pericardiocentesis procedure may be used to remove fluid build-up around the heart or extract blood clots. This can help reduce pressure on the heart muscle and reduce the risk of further medical complications. Additionally, certain medications may be injected through the catheter during this procedure in order to treat certain types of arrhythmias (irregular heartbeats) or bleeding within the pericardial sac.
Disease Indication Outlook
Recent studies have shown that pericardiocentesis procedures can be used to accurately predict the presence of cardiac illnesses such as pulmonary embolism, pericardial tamponade and constrictive pericarditis, as well as aid in the management of more serious complications such as ventricular arrhythmia and cardiomyopathy. In addition, research has also suggested that there is potential for this technique to be used for therapeutic purposes, such as removing blood clots or reducing fluid build-up around the heart. With its relatively low risk profile and ability to provide a wealth of diagnostic information, pericardiocentesis procedures market has become an increasingly popular procedure among medical professionals worldwide.
Region Outlook
In North America, the pericardiocentesis procedures market is driven by increasing prevalence of cardiovascular diseases and rising investments in medical technology. Additionally, developments in healthcare infrastructure have led to a significant increase in the number of hospitals offering specialized services such as pericardiocentesis. Furthermore, government programs aimed at providing greater access to advanced medical care have also contributed to the growth of the North American market for pericardiocentesis procedures market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global pericardiocentesis procedures market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key players operating in the global pericardiocentesis procedures market are:
- Apollo Hospitals Enterprise Limited
- Cleveland Clinic
- The Johns Hopkins Hospital
- The Mesothelioma Center
- The Ohio State University Wexner Medical Center
- University Hospitals
- Weill Cornell Medicine
- Winchester Hospital
- Other Market Participants
Global Pericardiocentesis Procedures Market:
By Type
- Therapeutic Procedure
- Diagnostic Procedure
By Technique
- Fluoroscopy-guided Technique
- Ultrasound- guided Technique
- Computed Tomography- guided Technique
- Others
By Disease Indication
- Infections
- Viral (including HIV)
- Bacterial
- Mycobacterial
- Fungal and Protozoal
- Infection of the Heart or Pericardial Sac
- Surgery or Invasive Heart Procedures
- Chest Trauma
- Malignancy
- Lung
- Breast
- Lymphoma
- Melanoma
- Others
- Immune System Disease
- Reactions to certain drugs
- Radiation
- Kidney (renal) Failure
- Others
By Healthcare Settings
- Hospitals and Clinics
- Cardiac Centers
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1.
Historic Years: 2015 - 2021
1.2.2.
Base Year: 2022
1.2.3.
Forecast Years: 2023 – 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1.
Research Questionnaire
3.1.2.
Global Percentage Breakdown
3.1.3.
Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1.
Paid Databases
3.2.2.
Secondary Sources
3.3. Market Size Estimates
3.3.1.
Top-Down Approach
3.3.2.
Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights
from AMI’s Perspective**
5. Holistic Overview of Pericardiocentesis Procedures Market
6. Market Synopsis: Pericardiocentesis Procedures Market
7. Pericardiocentesis
Procedures Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1.
Product Definition
7.1.2.
Industry Development
7.2. Market Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.3. Trends in Pericardiocentesis Procedures Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Pericardiocentesis Procedures Market
7.6. Porter’s Five Force Analysis
7.7. Impact Covid-19
on Pericardiocentesis Procedures Market
8. Global Pericardiocentesis Procedures Market Analysis and Forecasts, 2023 – 2031
8.1. Overview
8.1.1.
Global Pericardiocentesis Procedures Market Revenue (US$ Mn)
8.2. Global Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
8.2.1.
Therapeutic Procedure
8.2.1.1.
Definition
8.2.1.2.
Market Estimation and Penetration, 2015 – 2022
8.2.1.3.
Market Forecast, 2023 – 2031
8.2.1.4.
Compound Annual Growth
Rate (CAGR)
8.2.1.5.
Regional Bifurcation
8.2.1.5.1.
North America
8.2.1.5.1.1.
Market Estimation, 2015 – 2022
8.2.1.5.1.2.
Market Forecast, 2023 – 2031
8.2.1.5.2.
Europe
8.2.1.5.2.1.
Market Estimation, 2015 – 2022
8.2.1.5.2.2.
Market Forecast, 2023 – 2031
8.2.1.5.3.
Asia Pacific
8.2.1.5.3.1.
Market Estimation, 2015 – 2022
8.2.1.5.3.2.
Market Forecast, 2023 – 2031
8.2.1.5.4.
Middle East and Africa
8.2.1.5.4.1.
Market Estimation, 2015 – 2022
8.2.1.5.4.2.
Market Forecast, 2023 – 2031
8.2.1.5.5.
Latin America
8.2.1.5.5.1.
Market Estimation, 2015 – 2022
8.2.1.5.5.2.
Market Forecast, 2023 – 2031
8.2.2.
Diagnostic Procedure
8.2.2.1.
Definition
8.2.2.2.
Market Estimation and Penetration, 2015 – 2022
8.2.2.3.
Market Forecast, 2023 – 2031
8.2.2.4.
Compound Annual Growth
Rate (CAGR)
8.2.2.5.
Regional Bifurcation
8.2.2.5.1.
North America
8.2.2.5.1.1.
Market Estimation, 2015 – 2022
8.2.2.5.1.2.
Market Forecast, 2023 – 2031
8.2.2.5.2.
Europe
8.2.2.5.2.1.
Market Estimation, 2015 – 2022
8.2.2.5.2.2.
Market Forecast, 2023 – 2031
8.2.2.5.3.
Asia Pacific
8.2.2.5.3.1.
Market Estimation, 2015 – 2022
8.2.2.5.3.2.
Market Forecast, 2023 – 2031
8.2.2.5.4.
Middle East and Africa
8.2.2.5.4.1.
Market Estimation, 2015 – 2022
8.2.2.5.4.2.
Market Forecast, 2023 – 2031
8.2.2.5.5.
Latin America
8.2.2.5.5.1.
Market Estimation, 2015 – 2022
8.2.2.5.5.2.
Market Forecast, 2023 – 2031
8.3. Key Segment for Channeling Investments
8.3.1.
By Type
9. Global Pericardiocentesis Procedures Market Analysis and Forecasts, 2023 – 2031
9.1. Overview
9.2.
Global Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Technique
9.2.1.
Fluoroscopy-guided Technique
9.2.1.1.
Definition
9.2.1.2.
Market Estimation and Penetration, 2015 – 2022
9.2.1.3.
Market Forecast, 2023 – 2031
9.2.1.4.
Compound Annual Growth
Rate (CAGR)
9.2.1.5.
Regional Bifurcation
9.2.1.5.1.
North America
9.2.1.5.1.1.
Market Estimation, 2015 – 2022
9.2.1.5.1.2.
Market Forecast, 2023 – 2031
9.2.1.5.2.
Europe
9.2.1.5.2.1.
Market Estimation, 2015 – 2022
9.2.1.5.2.2.
Market Forecast, 2023 – 2031
9.2.1.5.3.
Asia Pacific
9.2.1.5.3.1.
Market Estimation, 2015 – 2022
9.2.1.5.3.2.
Market Forecast, 2023 – 2031
9.2.1.5.4.
Middle East and Africa
9.2.1.5.4.1.
Market Estimation, 2015 – 2022
9.2.1.5.4.2.
Market Forecast, 2023 – 2031
9.2.1.5.5.
Latin America
9.2.1.5.5.1.
Market Estimation, 2015 – 2022
9.2.1.5.5.2.
Market Forecast, 2023 – 2031
9.2.2.
Ultrasound- guided Technique
9.2.2.1.
Definition
9.2.2.2.
Market Estimation and Penetration, 2015 – 2022
9.2.2.3.
Market Forecast, 2023 – 2031
9.2.2.4.
Compound Annual Growth
Rate (CAGR)
9.2.2.5.
Regional Bifurcation
9.2.2.5.1.
North America
9.2.2.5.1.1.
Market Estimation, 2015 – 2022
9.2.2.5.1.2.
Market Forecast, 2023 – 2031
9.2.2.5.2.
Europe
9.2.2.5.2.1.
Market Estimation, 2015 – 2022
9.2.2.5.2.2.
Market Forecast, 2023 – 2031
9.2.2.5.3.
Asia Pacific
9.2.2.5.3.1.
Market Estimation, 2015 – 2022
9.2.2.5.3.2.
Market Forecast, 2023 – 2031
9.2.2.5.4.
Middle East and Africa
9.2.2.5.4.1.
Market Estimation, 2015 – 2022
9.2.2.5.4.2.
Market Forecast, 2023 – 2031
9.2.2.5.5.
Latin America
9.2.2.5.5.1.
Market Estimation, 2015 – 2022
9.2.2.5.5.2.
Market Forecast, 2023 – 2031
9.2.3.
Computed Tomography- guided
Technique
9.2.3.1.
Definition
9.2.3.2.
Market Estimation and Penetration, 2015 – 2022
9.2.3.3.
Market Forecast, 2023 – 2031
9.2.3.4.
Compound Annual Growth
Rate (CAGR)
9.2.3.5.
Regional Bifurcation
9.2.3.5.1.
North America
9.2.3.5.1.1.
Market Estimation, 2015 – 2022
9.2.3.5.1.2.
Market Forecast, 2023 – 2031
9.2.3.5.2.
Europe
9.2.3.5.2.1.
Market Estimation, 2015 – 2022
9.2.3.5.2.2.
Market Forecast, 2023 – 2031
9.2.3.5.3.
Asia Pacific
9.2.3.5.3.1.
Market Estimation, 2015 – 2022
9.2.3.5.3.2.
Market Forecast, 2023 – 2031
9.2.3.5.4.
Middle East and Africa
9.2.3.5.4.1.
Market Estimation, 2015 – 2022
9.2.3.5.4.2.
Market Forecast, 2023 – 2031
9.2.3.5.5.
Latin America
9.2.3.5.5.1.
Market Estimation, 2015 – 2022
9.2.3.5.5.2.
Market Forecast, 2023 – 2031
9.2.4.
Others
9.2.4.1.
Definition
9.2.4.2.
Market Estimation and Penetration, 2015 – 2022
9.2.4.3.
Market Forecast, 2023 – 2031
9.2.4.4.
Compound Annual Growth
Rate (CAGR)
9.2.4.5.
Regional Bifurcation
9.2.4.5.1.
North America
9.2.4.5.1.1.
Market Estimation, 2015 – 2022
9.2.4.5.1.2.
Market Forecast, 2023 – 2031
9.2.4.5.2.
Europe
9.2.4.5.2.1.
Market Estimation, 2015 – 2022
9.2.4.5.2.2.
Market Forecast, 2023 – 2031
9.2.4.5.3.
Asia Pacific
9.2.4.5.3.1.
Market Estimation, 2015 – 2022
9.2.4.5.3.2.
Market Forecast, 2023 – 2031
9.2.4.5.4.
Middle East and Africa
9.2.4.5.4.1.
Market Estimation, 2015 – 2022
9.2.4.5.4.2.
Market Forecast, 2023 – 2031
9.2.4.5.5.
Latin America
9.2.4.5.5.1.
Market Estimation, 2015 – 2022
9.2.4.5.5.2.
Market Forecast, 2023 – 2031
9.3. Key Segment for Channeling Investments
9.3.1.
By Technique
10. Global Pericardiocentesis Procedures Market Analysis and Forecasts, 2023 – 2031
10.1. Overview
10.2.
Global Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
10.2.1. Infections
(Definition, Market Estimation and Penetration, 2015 – 2022, Market Estimation
(2015 – 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America,
Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Viral (including HIV), Bacterial, Mycobacterial,
Fungal and Protozoal)
10.2.1.1.
Viral (including HIV)
10.2.1.2.
Bacterial
10.2.1.3.
Mycobacterial
10.2.1.4.
Fungal and Protozoal
10.2.2.
Infection of the Heart or Pericardial Sac
10.2.2.1.
Definition
10.2.2.2.
Market Estimation and Penetration, 2015 – 2022
10.2.2.3.
Market Forecast, 2023 – 2031
10.2.2.4.
Compound Annual Growth
Rate (CAGR)
10.2.2.5.
Regional Bifurcation
10.2.2.5.1.
North America
10.2.2.5.1.1.
Market Estimation, 2015 – 2022
10.2.2.5.1.2. Market Forecast,
2023 – 2031
10.2.2.5.2.
Europe
10.2.2.5.2.1.
Market Estimation, 2015 – 2022
10.2.2.5.2.2.
Market Forecast, 2023 – 2031
10.2.2.5.3.
Asia Pacific
10.2.2.5.3.1.
Market Estimation, 2015 – 2022
10.2.2.5.3.2. Market Forecast, 2023 – 2031 10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2022
10.2.2.5.4.2. Market Forecast,
2023 – 2031
10.2.2.5.5.
Latin America
10.2.2.5.5.1.
Market Estimation, 2015 – 2022
10.2.2.5.5.2. Market Forecast,
2023 – 2031
10.2.3.
Surgery or Invasive
Heart Procedures
10.2.3.1.
Definition
10.2.3.2.
Market Estimation and Penetration, 2015 – 2022
10.2.3.3.
Market Forecast, 2023 – 2031
10.2.3.4.
Compound Annual Growth
Rate (CAGR)
10.2.3.5.
Regional Bifurcation
10.2.3.5.1.
North America
10.2.3.5.1.1. Market Estimation, 2015 – 2022
10.2.3.5.1.2.
Market Forecast, 2023 – 2031
10.2.3.5.2.
Europe
10.2.3.5.2.1.
Market Estimation, 2015 – 2022
10.2.3.5.2.2. Market Forecast,
2023 – 2031
10.2.3.5.3.
Asia Pacific
10.2.3.5.3.1.
Market Estimation, 2015 – 2022
10.2.3.5.3.2. Market Forecast, 2023 – 2031 10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 – 2022
10.2.3.5.4.2. Market Forecast,
2023 – 2031
10.2.3.5.5.
Latin America
10.2.3.5.5.1. Market Estimation, 2015 – 2022
10.2.3.5.5.2.
Market Forecast, 2023 – 2031
10.2.4.
Chest Trauma
10.2.4.1.
Definition
10.2.4.2.
Market Estimation and Penetration, 2015 – 2022
10.2.4.3.
Market Forecast, 2023 – 2031
10.2.4.4.
Compound Annual Growth
Rate (CAGR)
10.2.4.5.
Regional Bifurcation
10.2.4.5.1.
North America
10.2.4.5.1.1.
Market Estimation, 2015 – 2022
10.2.4.5.1.2.
Market Forecast, 2023 – 2031
10.2.4.5.2.
Europe
10.2.4.5.2.1.
Market Estimation, 2015 – 2022
10.2.4.5.2.2.
Market Forecast, 2023 – 2031
10.2.4.5.3.
Asia Pacific
10.2.4.5.3.1.
Market Estimation, 2015 – 2022
10.2.4.5.3.2. Market Forecast, 2023 – 2031 10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 – 2022
10.2.4.5.4.2. Market Forecast,
2023 – 2031
10.2.4.5.5.
Latin America
10.2.4.5.5.1.
Market Estimation, 2015 – 2022
10.2.4.5.5.2.
Market Forecast, 2023 – 2031
10.2.5. Malignancy
(Definition, Market Estimation and Penetration, 2015 – 2022, Market Estimation
(2015 – 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa,
Latin America) and Information on Lung, Breast,
Lymphoma, Melanoma, Others)
10.2.5.1.
Lung
10.2.5.2.
Breast
10.2.5.3.
Lymphoma
10.2.5.4.
Melanoma
10.2.5.5.
Others
10.2.6.
Immune System Disease
10.2.6.1.
Definition
10.2.6.2.
Market Estimation and Penetration, 2015 – 2022
10.2.6.3.
Market Forecast, 2023 – 2031
10.2.6.4.
Compound Annual Growth
Rate (CAGR)
10.2.6.5.
Regional Bifurcation
10.2.6.5.1.
North America
10.2.6.5.1.1. Market Estimation, 2015 – 2022
10.2.6.5.1.2.
Market Forecast, 2023 – 2031
10.2.6.5.2.
Europe
10.2.6.5.2.1.
Market Estimation, 2015 – 2022
10.2.6.5.2.2.
Market Forecast, 2023 – 2031
10.2.6.5.3.
Asia Pacific
10.2.6.5.3.1.
Market Estimation, 2015 – 2022
10.2.6.5.3.2. Market Forecast, 2023 – 2031 10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 – 2022
10.2.6.5.4.2.
Market Forecast, 2023 – 2031
10.2.6.5.5.
Latin America
10.2.6.5.5.1.
Market Estimation, 2015 – 2022
10.2.6.5.5.2. Market Forecast,
2023 – 2031
10.2.7.
Reactions to certain
drugs
10.2.7.1.
Definition
10.2.7.2.
Market Estimation and Penetration, 2015 – 2022
10.2.7.3.
Market Forecast, 2023 – 2031
10.2.7.4.
Compound Annual Growth
Rate (CAGR)
10.2.7.5.
Regional Bifurcation
10.2.7.5.1.
North America
10.2.7.5.1.1.
Market Estimation, 2015 – 2022
10.2.7.5.1.2.
Market Forecast, 2023 – 2031
10.2.7.5.2.
Europe
10.2.7.5.2.1. Market Estimation, 2015 – 2022
10.2.7.5.2.2.
Market Forecast, 2023 – 2031
10.2.7.5.3.
Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 – 2022
10.2.7.5.3.2. Market Forecast, 2023 – 2031 10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 – 2022
10.2.7.5.4.2.
Market Forecast, 2023 – 2031
10.2.7.5.5.
Latin America
10.2.7.5.5.1. Market Estimation, 2015 – 2022
10.2.7.5.5.2.
Market Forecast, 2023 – 2031
10.2.8.
Radiation
10.2.8.1.
Definition
10.2.8.2.
Market Estimation and Penetration, 2015 – 2022
10.2.8.3.
Market Forecast, 2023 – 2031
10.2.8.4.
Compound Annual Growth
Rate (CAGR)
10.2.8.5.
Regional Bifurcation
10.2.8.5.1.
North America
10.2.8.5.1.1.
Market Estimation, 2015 – 2022
10.2.8.5.1.2.
Market Forecast, 2023 – 2031
10.2.8.5.2.
Europe
10.2.8.5.2.1.
Market Estimation, 2015 – 2022
10.2.8.5.2.2. Market Forecast,
2023 – 2031
10.2.8.5.3.
Asia Pacific
10.2.8.5.3.1.
Market Estimation, 2015 – 2022
10.2.8.5.3.2. Market Forecast, 2023 – 2031 10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2015 – 2022
10.2.8.5.4.2. Market Forecast,
2023 – 2031
10.2.8.5.5.
Latin America
10.2.8.5.5.1.
Market Estimation, 2015 – 2022
10.2.8.5.5.2. Market Forecast,
2023 – 2031
10.2.9.
Kidney (renal) Failure
10.2.9.1.
Definition
10.2.9.2.
Market Estimation and Penetration, 2015 – 2022
10.2.9.3.
Market Forecast, 2023 – 2031
10.2.9.4.
Compound Annual Growth
Rate (CAGR)
10.2.9.5.
Regional Bifurcation
10.2.9.5.1.
North America
10.2.9.5.1.1. Market Estimation, 2015 – 2022
10.2.9.5.1.2.
Market Forecast, 2023 – 2031
10.2.9.5.2.
Europe
10.2.9.5.2.1. Market Estimation, 2015 – 2022
10.2.9.5.2.2.
Market Forecast, 2023 – 2031
10.2.9.5.3.
Asia Pacific
10.2.9.5.3.1.
Market Estimation, 2015 – 2022
10.2.9.5.3.2. Market Forecast, 2023 – 2031 10.2.9.5.4. Middle East and Africa
10.2.9.5.4.1. Market Estimation, 2015 – 2022
10.2.9.5.4.2.
Market Forecast, 2023 – 2031
10.2.9.5.5.
Latin America
10.2.9.5.5.1.
Market Estimation, 2015 – 2022
10.2.9.5.5.2. Market Forecast,
2023 – 2031
10.2.10.
Others
10.2.10.1.
Definition
10.2.10.2.
Market Estimation and Penetration, 2015 – 2022
10.2.10.3.
Market Forecast, 2023 – 2031
10.2.10.4.
Compound Annual Growth
Rate (CAGR)
10.2.10.5.
Regional Bifurcation
10.2.10.5.1.
North America
10.2.10.5.1.1.
Market Estimation, 2015 – 2022
10.2.10.5.1.2.
Market Forecast, 2023 – 2031
10.2.10.5.2.
Europe
10.2.10.5.2.1.
Market Estimation, 2015 – 2022
10.2.10.5.2.2.
Market Forecast, 2023 – 2031
10.2.10.5.3.
Asia Pacific
10.2.10.5.3.1.
Market Estimation, 2015 – 2022
10.2.10.5.3.2. Market Forecast, 2023 – 2031 10.2.10.5.4. Middle East and Africa
10.2.10.5.4.1.
Market Estimation, 2015 – 2022
10.2.10.5.4.2.
Market Forecast, 2023 – 2031
10.2.10.5.5.
Latin America
10.2.10.5.5.1.
Market Estimation, 2015 – 2022
10.2.10.5.5.2.
Market Forecast, 2023 – 2031
10.3. Key Segment for Channeling Investments
10.3.1.
By Disease Indication
11. Global Pericardiocentesis Procedures Market Analysis and Forecasts, 2023 – 2031
11.1. Overview
11.2.
Global Pericardiocentesis
Procedures Market Revenue (US$ Mn)
and Forecasts, By Healthcare Setting
11.2.1.
Hospitals and Clinics
11.2.1.1.
Definition
11.2.1.2.
Market Estimation and Penetration, 2015 – 2022
11.2.1.3.
Market Forecast, 2023 – 2031
11.2.1.4.
Compound Annual Growth
Rate (CAGR)
11.2.1.5.
Regional Bifurcation
11.2.1.5.1.
North America
11.2.1.5.1.1.
Market Estimation, 2015 – 2022
11.2.1.5.1.2. Market Forecast,
2023 – 2031
11.2.1.5.2.
Europe
11.2.1.5.2.1.
Market Estimation, 2015 – 2022
11.2.1.5.2.2. Market Forecast,
2023 – 2031
11.2.1.5.3.
Asia Pacific
11.2.1.5.3.1.
Market Estimation, 2015 – 2022
11.2.1.5.3.2. Market Forecast, 2023 – 2031 11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 – 2022
11.2.1.5.4.2.
Market Forecast, 2023 – 2031
11.2.1.5.5.
Latin America
11.2.1.5.5.1.
Market Estimation, 2015 – 2022
11.2.1.5.5.2. Market Forecast,
2023 – 2031
11.2.2.
Cardiac Centers
11.2.2.1.
Definition
11.2.2.2.
Market Estimation and Penetration, 2015 – 2022
11.2.2.3.
Market Forecast, 2023 – 2031
11.2.2.4.
Compound Annual Growth
Rate (CAGR)
11.2.2.5.
Regional Bifurcation
11.2.2.5.1.
North America
11.2.2.5.1.1.
Market Estimation, 2015 – 2022
11.2.2.5.1.2. Market Forecast,
2023 – 2031
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 – 2022
11.2.2.5.2.2.
Market Forecast, 2023 – 2031
11.2.2.5.3.
Asia Pacific
11.2.2.5.3.1.
Market Estimation, 2015 – 2022
11.2.2.5.3.2. Market Forecast, 2023 – 2031 11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 – 2022
11.2.2.5.4.2.
Market Forecast, 2023 – 2031
11.2.2.5.5.
Latin America
11.2.2.5.5.1. Market Estimation, 2015 – 2022
11.2.2.5.5.2.
Market Forecast, 2023 – 2031
11.2.3.
Others
11.2.3.1.
Definition
11.2.3.2.
Market Estimation and Penetration, 2015 – 2022
11.2.3.3.
Market Forecast, 2023 – 2031
11.2.3.4.
Compound Annual Growth
Rate (CAGR)
11.2.3.5.
Regional Bifurcation
11.2.3.5.1.
North America
11.2.3.5.1.1. Market Estimation, 2015 – 2022
11.2.3.5.1.2.
Market Forecast, 2023 – 2031
11.2.3.5.2.
Europe
11.2.3.5.2.1.
Market Estimation, 2015 – 2022
11.2.3.5.2.2.
Market Forecast, 2023 – 2031
11.2.3.5.3.
Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 – 2022
11.2.3.5.3.2.
Market Forecast, 2023 – 2031
11.2.3.5.4.
Middle East and Africa
11.2.3.5.4.1.
Market Estimation, 2015 – 2022
11.2.3.5.4.2. Market Forecast,
2023 – 2031
11.2.3.5.5.
Latin America
11.2.3.5.5.1.
Market Estimation, 2015 – 2022
11.2.3.5.5.2.
Market Forecast, 2023 – 2031
11.3. Key Segment for Channeling Investments
11.3.1.
By Healthcare Setting
12. North America Pericardiocentesis Procedures Market Analysis
and Forecasts, 2023 – 2031
12.1. Overview
12.1.1.
North America Pericardiocentesis Procedures Market Revenue
(US$ Mn)
12.2.
North America Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
12.2.1.
Therapeutic Procedure
12.2.2.
Diagnostic Procedure
12.3.
North America Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
12.3.1.
Fluoroscopy-guided Technique
12.3.2.
Ultrasound- guided Technique
12.3.3.
Computed Tomography- guided
Technique
12.3.4.
Others
12.4.
North America Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
12.4.1.
Infections
12.4.1.1.
Viral (including HIV)
12.4.1.2.
Bacterial
12.4.1.3.
Mycobacterial
12.4.1.4.
Fungal and Protozoal
12.4.2.
Infection of the Heart or Pericardial Sac
12.4.3.
Surgery or Invasive
Heart Procedures
12.4.4.
Chest Trauma
12.4.5.
Malignancy
12.4.5.1.
Lung
12.4.5.2.
Breast
12.4.5.3.
Lymphoma
12.4.5.4.
Melanoma
12.4.5.5.
Others
12.4.6.
Immune System Disease
12.4.7.
Reactions to certain
drugs
12.4.8.
Radiation
12.4.9.
Kidney (renal) Failure
12.4.10.
Others
12.5.
North America Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
12.5.1.
Hospitals and Clinics
12.5.2.
Cardiac Centers
12.5.3.
Others
12.6.
North America Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1.
U.S
12.6.1.1. U.S Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
12.6.1.1.1.
Therapeutic Procedure
12.6.1.1.2.
Diagnostic Procedure
12.6.1.2. U.S Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
12.6.1.2.1. Fluoroscopy-guided Technique 12.6.1.2.2. Ultrasound- guided
Technique
12.6.1.2.3. Computed Tomography- guided Technique
12.6.1.2.4. Others
12.6.1.3. U.S Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
12.6.1.3.1.
Infections
12.6.1.3.1.1. Viral (including HIV) 12.6.1.3.1.2. Bacterial
12.6.1.3.1.3. Mycobacterial 12.6.1.3.1.4. Fungal and Protozoal
12.6.1.3.2. Infection of the Heart
or Pericardial Sac 12.6.1.3.3. Surgery or Invasive Heart
Procedures 12.6.1.3.4. Chest Trauma
12.6.1.3.5.
Malignancy
12.6.1.3.5.1. Lung
12.6.1.3.5.2.
Breast
12.6.1.3.5.3. Lymphoma
12.6.1.3.5.4.
Melanoma
12.6.1.3.5.5.
Others
12.6.1.3.6. Immune
System Disease 12.6.1.3.7. Reactions to certain drugs 12.6.1.3.8. Radiation
12.6.1.3.9. Kidney (renal)
Failure 12.6.1.3.10. Others
12.6.1.4. U.S Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Cardiac Centers
12.6.1.4.3. Others
12.6.2.
Canada
12.6.2.1. Canada Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
12.6.2.1.1.
Therapeutic Procedure
12.6.2.1.2.
Diagnostic Procedure
12.6.2.2. Canada Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
12.6.2.2.1. Fluoroscopy-guided Technique 12.6.2.2.2. Ultrasound- guided
Technique
12.6.2.2.3. Computed Tomography- guided Technique
12.6.2.2.4. Others
12.6.2.3. Canada Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
12.6.2.3.1.
Infections
12.6.2.3.1.1. Viral (including HIV) 12.6.2.3.1.2. Bacterial
12.6.2.3.1.3. Mycobacterial 12.6.2.3.1.4. Fungal and Protozoal
12.6.2.3.2. Infection of the Heart
or Pericardial Sac 12.6.2.3.3. Surgery or Invasive Heart
Procedures 12.6.2.3.4. Chest Trauma
12.6.2.3.5.
Malignancy
12.6.2.3.5.1.
Lung
12.6.2.3.5.2. Breast
12.6.2.3.5.3.
Lymphoma
12.6.2.3.5.4.
Melanoma
12.6.2.3.5.5. Others
12.6.2.3.6. Immune
System Disease 12.6.2.3.7. Reactions to certain drugs 12.6.2.3.8. Radiation
12.6.2.3.9. Kidney (renal)
Failure 12.6.2.3.10. Others
12.6.2.4. Canada Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Cardiac Centers
12.6.2.4.3. Others
12.6.3.
Mexico
12.6.3.1. Mexico Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
12.6.3.1.1.
Therapeutic Procedure
12.6.3.1.2.
Diagnostic Procedure
12.6.3.2. Mexico Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
12.6.3.2.1. Fluoroscopy-guided Technique 12.6.3.2.2. Ultrasound- guided
Technique
12.6.3.2.3. Computed Tomography- guided Technique
12.6.3.2.4. Others
12.6.3.3. Mexico Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
12.6.3.3.1.
Infections
12.6.3.3.1.1. Viral (including HIV) 12.6.3.3.1.2. Bacterial
12.6.3.3.1.3. Mycobacterial 12.6.3.3.1.4. Fungal and Protozoal
12.6.3.3.2. Infection of the Heart
or Pericardial Sac 12.6.3.3.3. Surgery or Invasive Heart
Procedures 12.6.3.3.4. Chest Trauma
12.6.3.3.5.
Malignancy
12.6.3.3.5.1.
Lung
12.6.3.3.5.2.
Breast
12.6.3.3.5.3.
Lymphoma
12.6.3.3.5.4.
Melanoma
12.6.3.3.5.5. Others
12.6.3.3.6. Immune
System Disease 12.6.3.3.7. Reactions to certain drugs 12.6.3.3.8. Radiation
12.6.3.3.9. Kidney (renal)
Failure 12.6.3.3.10. Others
12.6.3.4. Mexico Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
12.6.3.4.1.
Hospitals and Clinics
12.6.3.4.2.
Cardiac Centers
12.6.3.4.3.
Others
12.6.4.
Rest of North
America
12.6.4.1. Rest of North America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Type
12.6.4.1.1.
Therapeutic Procedure
12.6.4.1.2.
Diagnostic Procedure
12.6.4.2. Rest of North America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Technique
12.6.4.2.1. Fluoroscopy-guided Technique 12.6.4.2.2. Ultrasound- guided
Technique
12.6.4.2.3. Computed Tomography- guided Technique
12.6.4.2.4. Others
12.6.4.3. Rest of North America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
12.6.4.3.1.
Infections
12.6.4.3.1.1. Viral (including HIV) 12.6.4.3.1.2. Bacterial
12.6.4.3.1.3. Mycobacterial 12.6.4.3.1.4. Fungal and Protozoal
12.6.4.3.2. Infection of the Heart
or Pericardial Sac 12.6.4.3.3. Surgery or Invasive Heart
Procedures 12.6.4.3.4. Chest Trauma
12.6.4.3.5.
Malignancy
12.6.4.3.5.1.
Lung
12.6.4.3.5.2.
Breast
12.6.4.3.5.3.
Lymphoma
12.6.4.3.5.4. Melanoma
12.6.4.3.5.5.
Others
12.6.4.3.6. Immune
System Disease 12.6.4.3.7. Reactions to certain drugs 12.6.4.3.8. Radiation
12.6.4.3.9. Kidney (renal)
Failure 12.6.4.3.10. Others
12.6.4.4. Rest of North America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Healthcare Setting
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Cardiac Centers
12.6.4.4.3. Others
12.7. Key Segment
for Channeling Investments
12.7.1.
By Country
12.7.2.
By Type
12.7.3.
By Technique
12.7.4.
By Disease Indication
12.7.5.
By Healthcare Setting
13. Europe Pericardiocentesis Procedures Market Analysis and Forecasts, 2023 – 2031
13.1. Overview
13.1.1.
Europe Pericardiocentesis Procedures Market Revenue (US$ Mn)
13.2. Europe Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
13.2.1.
Therapeutic Procedure
13.2.2.
Diagnostic Procedure
13.3.
Europe Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
13.3.1.
Fluoroscopy-guided Technique
13.3.2.
Ultrasound- guided Technique
13.3.3.
Computed Tomography- guided
Technique
13.3.4.
Others
13.4.
Europe Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.4.1.
Infections
13.4.1.1.
Viral (including HIV)
13.4.1.2.
Bacterial
13.4.1.3.
Mycobacterial
13.4.1.4.
Fungal and Protozoal
13.4.2.
Infection of the Heart or Pericardial Sac
13.4.3.
Surgery or Invasive
Heart Procedures
13.4.4.
Chest Trauma
13.4.5.
Malignancy
13.4.5.1.
Lung
13.4.5.2.
Breast
13.4.5.3.
Lymphoma
13.4.5.4.
Melanoma
13.4.5.5.
Others
13.4.6.
Immune System Disease
13.4.7.
Reactions to certain
drugs
13.4.8.
Radiation
13.4.9.
Kidney (renal) Failure
13.4.10.
Others
13.5.
Europe Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Healthcare Setting
13.5.1.
Hospitals and Clinics
13.5.2.
Cardiac Centers
13.5.3.
Others
13.6.
Europe Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1.
France
13.6.1.1. France Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
13.6.1.1.1.
Therapeutic Procedure
13.6.1.1.2.
Diagnostic Procedure
13.6.1.2. France Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
13.6.1.2.1. Fluoroscopy-guided Technique 13.6.1.2.2. Ultrasound- guided
Technique
13.6.1.2.3. Computed Tomography- guided Technique
13.6.1.2.4. Others
13.6.1.3. France Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
13.6.1.3.1.
Infections
13.6.1.3.1.1. Viral (including HIV) 13.6.1.3.1.2. Bacterial
13.6.1.3.1.3. Mycobacterial 13.6.1.3.1.4. Fungal and Protozoal
13.6.1.3.2. Infection of the Heart
or Pericardial Sac 13.6.1.3.3. Surgery or Invasive Heart
Procedures 13.6.1.3.4. Chest Trauma
13.6.1.3.5.
Malignancy
13.6.1.3.5.1.
Lung
13.6.1.3.5.2.
Breast
13.6.1.3.5.3.
Lymphoma
13.6.1.3.5.4. Melanoma
13.6.1.3.5.5.
Others
13.6.1.3.6. Immune
System Disease 13.6.1.3.7. Reactions to certain drugs 13.6.1.3.8. Radiation
13.6.1.3.9. Kidney (renal)
Failure 13.6.1.3.10. Others
13.6.1.4. France Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Cardiac Centers
13.6.1.4.3. Others
13.6.2.
The UK
13.6.2.1. The UK Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.1.1.
Therapeutic Procedure
13.6.2.1.2.
Diagnostic Procedure
13.6.2.2. The UK Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
13.6.2.2.1. Fluoroscopy-guided Technique 13.6.2.2.2. Ultrasound- guided
Technique
13.6.2.2.3. Computed Tomography- guided Technique
13.6.2.2.4. Others
13.6.2.3. The UK Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.6.2.3.1.
Infections
13.6.2.3.1.1. Viral (including HIV) 13.6.2.3.1.2. Bacterial
13.6.2.3.1.3. Mycobacterial 13.6.2.3.1.4. Fungal and Protozoal
13.6.2.3.2. Infection of the Heart
or Pericardial Sac 13.6.2.3.3. Surgery or Invasive Heart
Procedures 13.6.2.3.4. Chest Trauma
13.6.2.3.5.
Malignancy
13.6.2.3.5.1.
Lung
13.6.2.3.5.2.
Breast
13.6.2.3.5.3.
Lymphoma
13.6.2.3.5.4.
Melanoma
13.6.2.3.5.5. Others
13.6.2.3.6. Immune
System Disease 13.6.2.3.7. Reactions to certain drugs 13.6.2.3.8. Radiation
13.6.2.3.9. Kidney (renal)
Failure 13.6.2.3.10. Others
13.6.2.4. The UK Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Healthcare Setting
13.6.2.4.1.
Hospitals and Clinics
13.6.3.
Spain
13.6.2.4.2. Cardiac
Centers
13.6.2.4.3. Others
13.6.3.1. Spain Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
13.6.3.1.1.
Therapeutic Procedure
13.6.3.1.2.
Diagnostic Procedure
13.6.3.2. Spain Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
13.6.3.2.1. Fluoroscopy-guided Technique 13.6.3.2.2. Ultrasound- guided
Technique
13.6.3.2.3. Computed Tomography- guided Technique
13.6.3.2.4. Others
13.6.3.3. Spain Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
13.6.3.3.1.
Infections
13.6.3.3.1.1. Viral (including HIV) 13.6.3.3.1.2. Bacterial
13.6.3.3.1.3. Mycobacterial 13.6.3.3.1.4. Fungal and Protozoal
13.6.3.3.2. Infection of the Heart
or Pericardial Sac 13.6.3.3.3. Surgery or Invasive Heart
Procedures 13.6.3.3.4. Chest Trauma
13.6.3.3.5.
Malignancy
13.6.3.3.5.1.
Lung
13.6.3.3.5.2. Breast
13.6.3.3.5.3.
Lymphoma
13.6.3.3.5.4.
Melanoma
13.6.3.3.5.5.
Others
13.6.3.3.6. Immune
System Disease 13.6.3.3.7. Reactions to certain drugs 13.6.3.3.8. Radiation
13.6.3.3.9. Kidney (renal)
Failure 13.6.3.3.10. Others
13.6.3.4. Spain Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Cardiac Centers
13.6.3.4.3. Others
13.6.4.
Germany
13.6.4.1. Germany Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
13.6.4.1.1.
Therapeutic Procedure
13.6.4.1.2.
Diagnostic Procedure
13.6.4.2. Germany Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
13.6.4.2.1. Fluoroscopy-guided Technique 13.6.4.2.2. Ultrasound- guided
Technique
13.6.4.2.3. Computed Tomography- guided Technique 13.6.4.2.4.
Others
13.6.4.3. Germany Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
13.6.4.3.1.
Infections
13.6.4.3.1.1. Viral (including HIV) 13.6.4.3.1.2. Bacterial
13.6.4.3.1.3. Mycobacterial 13.6.4.3.1.4. Fungal and Protozoal
13.6.4.3.2. Infection of the Heart
or Pericardial Sac 13.6.4.3.3. Surgery or Invasive Heart
Procedures 13.6.4.3.4. Chest Trauma
13.6.4.3.5.
Malignancy
13.6.4.3.5.1.
Lung
13.6.4.3.5.2. Breast
13.6.4.3.5.3.
Lymphoma
13.6.4.3.5.4.
Melanoma
13.6.4.3.5.5. Others
13.6.4.3.6. Immune
System Disease 13.6.4.3.7. Reactions to certain drugs 13.6.4.3.8. Radiation
13.6.4.3.9. Kidney (renal)
Failure 13.6.4.3.10. Others
13.6.4.4. Germany Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Cardiac Centers
13.6.4.4.3. Others
13.6.5.
Italy
13.6.5.1. Italy Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
13.6.5.1.1.
Therapeutic Procedure
13.6.5.1.2.
Diagnostic Procedure
13.6.5.2. Italy Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
13.6.5.2.1. Fluoroscopy-guided Technique 13.6.5.2.2. Ultrasound- guided
Technique
13.6.5.2.3. Computed Tomography- guided Technique
13.6.5.2.4. Others
13.6.5.3. Italy Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
13.6.5.3.1.
Infections
13.6.5.3.1.1. Viral (including HIV) 13.6.5.3.1.2. Bacterial
13.6.5.3.1.3. Mycobacterial 13.6.5.3.1.4. Fungal and Protozoal
13.6.5.3.2. Infection of the Heart
or Pericardial Sac 13.6.5.3.3. Surgery or Invasive Heart
Procedures 13.6.5.3.4. Chest Trauma
13.6.5.3.5.
Malignancy
13.6.5.3.5.1.
Lung
13.6.5.3.5.2.
Breast
13.6.5.3.5.3.
Lymphoma
13.6.5.3.5.4.
Melanoma
13.6.5.3.5.5. Others
13.6.5.3.6. Immune
System Disease 13.6.5.3.7. Reactions to certain drugs 13.6.5.3.8. Radiation
13.6.5.3.9. Kidney (renal)
Failure 13.6.5.3.10. Others
13.6.5.4. Italy Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Cardiac Centers
13.6.5.4.3. Others
13.6.6.
Nordic Countries
13.6.6.1. Nordic Countries Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Type
13.6.6.1.1.
Therapeutic Procedure
13.6.6.1.2.
Diagnostic Procedure
13.6.6.2. Nordic Countries
Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Technique
13.6.6.2.1. Fluoroscopy-guided Technique 13.6.6.2.2. Ultrasound- guided
Technique
13.6.6.2.3. Computed Tomography- guided Technique
13.6.6.2.4. Others
13.6.6.3. Nordic Countries Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.6.6.3.1.
Infections
13.6.6.3.1.1. Viral (including HIV) 13.6.6.3.1.2. Bacterial
13.6.6.3.1.3. Mycobacterial 13.6.6.3.1.4. Fungal and Protozoal
13.6.6.3.2. Infection of the Heart
or Pericardial Sac 13.6.6.3.3. Surgery or Invasive Heart
Procedures 13.6.6.3.4. Chest Trauma
13.6.6.3.5.
Malignancy
13.6.6.3.5.1.
Lung
13.6.6.3.5.2.
Breast
13.6.6.3.5.3.
Lymphoma
13.6.6.3.5.4. Melanoma
13.6.6.3.5.5.
Others
13.6.6.3.6. Immune
System Disease 13.6.6.3.7. Reactions to certain drugs 13.6.6.3.8. Radiation
13.6.6.3.9. Kidney (renal)
Failure 13.6.6.3.10. Others
13.6.6.4. Nordic Countries Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Healthcare Setting
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Cardiac Centers
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Pericardiocentesis Procedures
Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7.
Benelux Union
13.6.7.1. Benelux Union
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Type
13.6.7.1.1.
Therapeutic Procedure
13.6.7.1.2.
Diagnostic Procedure
13.6.7.2. Benelux Union Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Technique
13.6.7.2.1. Fluoroscopy-guided Technique 13.6.7.2.2. Ultrasound- guided
Technique
13.6.7.2.3. Computed Tomography- guided Technique
13.6.7.2.4. Others
13.6.7.3. Benelux Union
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
13.6.7.3.1.
Infections
13.6.7.3.1.1. Viral (including HIV) 13.6.7.3.1.2. Bacterial
13.6.7.3.1.3. Mycobacterial 13.6.7.3.1.4. Fungal and Protozoal
13.6.7.3.2. Infection of the Heart
or Pericardial Sac 13.6.7.3.3. Surgery or Invasive Heart
Procedures 13.6.7.3.4. Chest Trauma
13.6.7.3.5.
Malignancy
13.6.7.3.5.1.
Lung
13.6.7.3.5.2.
Breast
13.6.7.3.5.3.
Lymphoma
13.6.7.3.5.4. Melanoma
13.6.7.3.5.5.
Others
13.6.7.3.6. Immune
System Disease 13.6.7.3.7. Reactions to certain drugs 13.6.7.3.8. Radiation
13.6.7.3.9. Kidney (renal)
Failure 13.6.7.3.10. Others
13.6.7.4. Benelux Union
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Healthcare Setting
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Cardiac Centers
13.6.7.4.3. Others
13.6.7.5. Benelux Union
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The Netherlands
13.6.7.5.3.
Luxembourg
13.6.8.
Rest of Europe
13.6.8.1. Rest of Europe Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By
Type
13.6.8.1.1.
Therapeutic Procedure
13.6.8.1.2.
Diagnostic Procedure
13.6.8.2. Rest of Europe Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By
Technique
13.6.8.2.1. Fluoroscopy-guided Technique 13.6.8.2.2. Ultrasound- guided
Technique
13.6.8.2.3. Computed Tomography- guided Technique
13.6.8.2.4. Others
13.6.8.3. Rest of Europe Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
13.6.8.3.1.
Infections
13.6.8.3.1.1. Viral (including HIV) 13.6.8.3.1.2. Bacterial
13.6.8.3.1.3. Mycobacterial 13.6.8.3.1.4. Fungal and Protozoal
13.6.8.3.2. Infection of the Heart
or Pericardial Sac 13.6.8.3.3. Surgery or Invasive Heart
Procedures 13.6.8.3.4. Chest Trauma
13.6.8.3.5.
Malignancy
13.6.8.3.5.1.
Lung
13.6.8.3.5.2. Breast
13.6.8.3.5.3.
Lymphoma
13.6.8.3.5.4.
Melanoma
13.6.8.3.5.5. Others
13.6.8.3.6. Immune
System Disease 13.6.8.3.7. Reactions to certain drugs 13.6.8.3.8. Radiation
13.6.8.3.9. Kidney (renal)
Failure 13.6.8.3.10. Others
13.6.8.4. Rest of Europe Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By
Healthcare Setting
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Cardiac Centers
13.6.8.4.3. Others
13.7. Key Segment
for Channeling Investments
13.7.1.
By Country
13.7.2.
By Type
13.7.3.
By Technique
13.7.4.
By Disease Indication
13.7.5.
By Healthcare Setting
14. Asia Pacific Pericardiocentesis Procedures Market Analysis
and Forecasts, 2023 – 2031
14.1. Overview
14.1.1.
Asia Pacific Pericardiocentesis Procedures Market Revenue
(US$ Mn)
14.2.
Asia Pacific Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1.
Therapeutic Procedure
14.2.2.
Diagnostic Procedure
14.3.
Asia Pacific Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
14.3.1.
Fluoroscopy-guided Technique
14.3.2.
Ultrasound- guided Technique
14.3.3.
Computed Tomography- guided
Technique
14.3.4.
Others
14.4.
Asia Pacific Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.4.1.
Infections
14.4.1.1.
Viral (including HIV)
14.4.1.2.
Bacterial
14.4.1.3.
Mycobacterial
14.4.1.4.
Fungal and Protozoal
14.4.2.
Infection of the Heart or Pericardial Sac
14.4.3.
Surgery or Invasive
Heart Procedures
14.4.4.
Chest Trauma
14.4.5.
Malignancy
14.4.5.1.
Lung
14.4.5.2.
Breast
14.4.5.3.
Lymphoma
14.4.5.4.
Melanoma
14.4.5.5.
Others
14.4.6.
Immune System Disease
14.4.7.
Reactions to certain
drugs
14.4.8.
Radiation
14.4.9.
Kidney (renal) Failure
14.4.10.
Others
14.5.
Asia Pacific Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By
Healthcare Setting
14.5.1.
Hospitals and Clinics
14.5.2.
Cardiac Centers
14.5.3.
Others
14.6.
Asia Pacific Pericardiocentesis
Procedures Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1.
China
14.6.1.1. China Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.1.1.1.
Therapeutic Procedure
14.6.1.1.2.
Diagnostic Procedure
14.6.1.2. China Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
14.6.1.2.1. Fluoroscopy-guided Technique 14.6.1.2.2. Ultrasound- guided
Technique
14.6.1.2.3. Computed Tomography- guided Technique
14.6.1.2.4. Others
14.6.1.3. China Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.1.3.1.
Infections
14.6.1.3.1.1. Viral (including HIV) 14.6.1.3.1.2. Bacterial
14.6.1.3.1.3. Mycobacterial 14.6.1.3.1.4. Fungal and Protozoal
14.6.1.3.2. Infection of the Heart
or Pericardial Sac 14.6.1.3.3. Surgery or Invasive Heart
Procedures 14.6.1.3.4. Chest Trauma
14.6.1.3.5.
Malignancy
14.6.1.3.5.1.
Lung
14.6.1.3.5.2. Breast
14.6.1.3.5.3.
Lymphoma
14.6.1.3.5.4.
Melanoma
14.6.1.3.5.5.
Others
14.6.1.3.6. Immune
System Disease 14.6.1.3.7. Reactions to certain drugs 14.6.1.3.8. Radiation
14.6.1.3.9. Kidney (renal)
Failure 14.6.1.3.10. Others
14.6.1.4. China Pericardiocentesis Procedures Market
Revenue (US$ Mn) and
Forecasts, By Healthcare Setting
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Cardiac Centers
14.6.1.4.3. Others
14.6.2.
Japan
14.6.2.1. Japan Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.2.1.1.
Therapeutic Procedure
14.6.2.1.2.
Diagnostic Procedure
14.6.2.2. Japan Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
14.6.2.2.1. Fluoroscopy-guided Technique 14.6.2.2.2. Ultrasound- guided
Technique
14.6.2.2.3. Computed Tomography- guided Technique
14.6.2.2.4. Others
14.6.2.3. Japan Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.2.3.1.
Infections
14.6.2.3.1.1. Viral (including HIV) 14.6.2.3.1.2. Bacterial
14.6.2.3.1.3. Mycobacterial 14.6.2.3.1.4. Fungal and Protozoal
14.6.2.3.2. Infection of the Heart
or Pericardial Sac 14.6.2.3.3. Surgery or Invasive Heart
Procedures 14.6.2.3.4. Chest Trauma
14.6.2.3.5.
Malignancy
14.6.2.3.5.1. Lung
14.6.2.3.5.2.
Breast
14.6.2.3.5.3.
Lymphoma
14.6.2.3.5.4. Melanoma
14.6.2.3.5.5.
Others
14.6.2.3.6. Immune
System Disease 14.6.2.3.7. Reactions to certain drugs 14.6.2.3.8. Radiation
14.6.2.3.9. Kidney (renal)
Failure 14.6.2.3.10. Others
14.6.2.4. Japan Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Cardiac Centers
14.6.2.4.3. Others
14.6.3.
India
14.6.3.1. India Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.3.1.1.
Therapeutic Procedure
14.6.3.1.2.
Diagnostic Procedure
14.6.3.2. India Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
14.6.3.2.1. Fluoroscopy-guided Technique 14.6.3.2.2. Ultrasound- guided
Technique
14.6.3.2.3. Computed Tomography- guided Technique
14.6.3.2.4. Others
14.6.3.3. India Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.3.3.1.
Infections
14.6.3.3.1.1. Viral (including HIV) 14.6.3.3.1.2. Bacterial
14.6.3.3.1.3. Mycobacterial 14.6.3.3.1.4. Fungal and Protozoal
14.6.3.3.2. Infection of the Heart
or Pericardial Sac 14.6.3.3.3. Surgery or Invasive Heart
Procedures 14.6.3.3.4. Chest Trauma
14.6.3.3.5.
Malignancy
14.6.3.3.5.1.
Lung
14.6.3.3.5.2.
Breast
14.6.3.3.5.3.
Lymphoma
14.6.3.3.5.4. Melanoma
14.6.3.3.5.5.
Others
14.6.3.3.6. Immune
System Disease 14.6.3.3.7. Reactions to certain drugs 14.6.3.3.8. Radiation
14.6.3.3.9. Kidney (renal)
Failure 14.6.3.3.10. Others
14.6.3.4. India Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Cardiac Centers
14.6.3.4.3. Others
14.6.4.
New Zealand
14.6.4.1. New Zealand
Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Type
14.6.4.1.1.
Therapeutic Procedure
14.6.4.1.2.
Diagnostic Procedure
14.6.4.2. New Zealand
Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Technique
14.6.4.2.1. Fluoroscopy-guided Technique 14.6.4.2.2. Ultrasound- guided
Technique
14.6.4.2.3. Computed Tomography- guided Technique
14.6.4.2.4. Others
14.6.4.3. New Zealand
Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
14.6.4.3.1.
Infections
14.6.4.3.1.1. Viral (including HIV) 14.6.4.3.1.2. Bacterial
14.6.4.3.1.3. Mycobacterial 14.6.4.3.1.4. Fungal and Protozoal
14.6.4.3.2. Infection of the Heart
or Pericardial Sac 14.6.4.3.3. Surgery or Invasive Heart
Procedures 14.6.4.3.4. Chest Trauma
14.6.4.3.5.
Malignancy
14.6.4.3.5.1.
Lung
14.6.4.3.5.2.
Breast
14.6.4.3.5.3.
Lymphoma
14.6.4.3.5.4. Melanoma
14.6.4.3.5.5.
Others
14.6.4.3.6. Immune
System Disease 14.6.4.3.7. Reactions to certain drugs 14.6.4.3.8. Radiation
14.6.4.3.9. Kidney (renal)
Failure 14.6.4.3.10. Others
14.6.4.4. New Zealand
Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Healthcare Setting
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Cardiac Centers
14.6.4.4.3. Others
14.6.5.
Australia
14.6.5.1. Australia Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
14.6.5.1.1.
Therapeutic Procedure
14.6.5.1.2.
Diagnostic Procedure
14.6.5.2. Australia Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
14.6.5.2.1.
Fluoroscopy-guided Technique
14.6.5.2.2.
Ultrasound- guided Technique
14.6.5.2.3. Computed Tomography- guided Technique
14.6.5.2.4. Others
14.6.5.3. Australia Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
14.6.5.3.1.
Infections
14.6.5.3.1.1. Viral (including HIV) 14.6.5.3.1.2. Bacterial
14.6.5.3.1.3. Mycobacterial 14.6.5.3.1.4. Fungal and Protozoal
14.6.5.3.2. Infection of the Heart
or Pericardial Sac 14.6.5.3.3. Surgery or Invasive Heart
Procedures 14.6.5.3.4. Chest Trauma
14.6.5.3.5.
Malignancy
14.6.5.3.5.1.
Lung
14.6.5.3.5.2.
Breast
14.6.5.3.5.3. Lymphoma
14.6.5.3.5.4.
Melanoma
14.6.5.3.5.5.
Others
14.6.5.3.6. Immune
System Disease 14.6.5.3.7. Reactions to certain drugs 14.6.5.3.8. Radiation
14.6.5.3.9. Kidney (renal)
Failure 14.6.5.3.10. Others
14.6.5.4. Australia Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By
Healthcare Setting
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Cardiac Centers
14.6.5.4.3. Others
14.6.6.
South Korea
14.6.6.1. South Korea
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.1.1.
Therapeutic Procedure
14.6.6.1.2.
Diagnostic Procedure
14.6.6.2. South Korea
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
14.6.6.2.1. Fluoroscopy-guided Technique 14.6.6.2.2. Ultrasound- guided
Technique
14.6.6.2.3. Computed Tomography- guided Technique
14.6.6.2.4. Others
14.6.6.3. South Korea
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.6.6.3.1.
Infections
14.6.6.3.1.1. Viral (including HIV) 14.6.6.3.1.2. Bacterial
14.6.6.3.1.3. Mycobacterial 14.6.6.3.1.4. Fungal and Protozoal
14.6.6.3.2. Infection of the Heart
or Pericardial Sac 14.6.6.3.3. Surgery or Invasive Heart
Procedures 14.6.6.3.4. Chest Trauma
14.6.6.3.5.
Malignancy
14.6.6.3.5.1. Lung
14.6.6.3.5.2.
Breast
14.6.6.3.5.3. Lymphoma
14.6.6.3.5.4.
Melanoma
14.6.6.3.5.5.
Others
14.6.6.3.6. Immune
System Disease 14.6.6.3.7. Reactions to certain drugs 14.6.6.3.8. Radiation
14.6.6.3.9. Kidney (renal)
Failure 14.6.6.3.10. Others
14.6.6.4. South Korea
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Healthcare Setting
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Cardiac Centers
14.6.6.4.3. Others
14.6.7.
Southeast Asia
14.6.7.1. Southeast Asia Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Type
14.6.7.1.1.
Therapeutic Procedure
14.6.7.1.2.
Diagnostic Procedure
14.6.7.2. Southeast Asia Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Technique
14.6.7.2.1. Fluoroscopy-guided Technique 14.6.7.2.2. Ultrasound- guided
Technique
14.6.7.2.3. Computed Tomography- guided Technique
14.6.7.2.4. Others
14.6.7.3. Southeast Asia Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
14.6.7.3.1.
Infections
14.6.7.3.1.1. Viral (including HIV) 14.6.7.3.1.2. Bacterial
14.6.7.3.1.3. Mycobacterial 14.6.7.3.1.4. Fungal and Protozoal
14.6.7.3.2. Infection of the Heart
or Pericardial Sac 14.6.7.3.3. Surgery or Invasive Heart
Procedures 14.6.7.3.4. Chest Trauma
14.6.7.3.5.
Malignancy
14.6.7.3.5.1.
Lung
14.6.7.3.5.2.
Breast
14.6.7.3.5.3. Lymphoma
14.6.7.3.5.4.
Melanoma
14.6.7.3.5.5. Others
14.6.7.3.6. Immune
System Disease 14.6.7.3.7. Reactions to certain drugs 14.6.7.3.8. Radiation
14.6.7.3.9. Kidney (renal)
Failure 14.6.7.3.10. Others
14.6.7.4. Southeast Asia Pericardiocentesis
Procedures Market Revenue
(US$ Mn) and Forecasts, By
Healthcare Setting
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Cardiac Centers
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Pericardiocentesis Procedures Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of Southeast Asia
14.6.8.
Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Type
14.6.8.1.1.
Therapeutic Procedure
14.6.8.1.2.
Diagnostic Procedure
14.6.8.2. Rest of Asia Pacific
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
14.6.8.2.1. Fluoroscopy-guided Technique 14.6.8.2.2. Ultrasound- guided
Technique
14.6.8.2.3.
Computed Tomography- guided
Technique
14.6.8.2.4.
Others
14.6.8.3. Rest of Asia Pacific
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.6.8.3.1.
Infections
14.6.8.3.1.1. Viral (including HIV) 14.6.8.3.1.2. Bacterial
14.6.8.3.1.3. Mycobacterial 14.6.8.3.1.4. Fungal and Protozoal
14.6.8.3.2. Infection of the Heart
or Pericardial Sac 14.6.8.3.3. Surgery or Invasive Heart
Procedures 14.6.8.3.4. Chest Trauma
14.6.8.3.5.
Malignancy
14.6.8.3.5.1.
Lung
14.6.8.3.5.2.
Breast
14.6.8.3.5.3.
Lymphoma
14.6.8.3.5.4. Melanoma
14.6.8.3.5.5.
Others
14.6.8.3.6. Immune
System Disease 14.6.8.3.7. Reactions to certain drugs 14.6.8.3.8. Radiation
14.6.8.3.9. Kidney (renal)
Failure 14.6.8.3.10. Others
14.6.8.4. Rest of Asia Pacific
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Healthcare
Setting
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Cardiac Centers
14.6.8.4.3. Others
14.7. Key Segment
for Channeling Investments
14.7.1.
By Country
14.7.2.
By Type
14.7.3.
By Technique
14.7.4.
By Disease Indication
14.7.5.
By Healthcare Setting
15. Middle East and Africa Pericardiocentesis Procedures Market Analysis and Forecasts, 2023 –
2031
15.1. Overview
15.1.1.
Middle East and Africa Pericardiocentesis Procedures Market Revenue
(US$ Mn)
15.2.
Middle East and Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1.
Therapeutic Procedure
15.2.2.
Diagnostic Procedure
15.3.
Middle East and Africa Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
15.3.1.
Fluoroscopy-guided Technique
15.3.2.
Ultrasound- guided Technique
15.3.3.
Computed Tomography- guided
Technique
15.3.4.
Others
15.4.
Middle East and Africa Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.4.1.
Infections
15.4.1.1.
Viral (including HIV)
15.4.1.2.
Bacterial
15.4.1.3.
Mycobacterial
15.4.1.4.
Fungal and Protozoal
15.4.2.
Infection of the Heart or Pericardial Sac
15.4.3.
Surgery or Invasive
Heart Procedures
15.4.4.
Chest Trauma
15.4.5.
Malignancy
15.4.5.1.
Lung
15.4.5.2.
Breast
15.4.5.3.
Lymphoma
15.4.5.4.
Melanoma
15.4.5.5.
Others
15.4.6.
Immune System Disease
15.4.7.
Reactions to certain
drugs
15.4.8.
Radiation
15.4.9.
Kidney (renal) Failure
15.4.10.
Others
15.5.
Middle East and Africa Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Healthcare Setting
15.5.1.
Hospitals and Clinics
15.5.2.
Cardiac Centers
15.5.3.
Others
15.6.
Middle East and Africa Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1.
Saudi Arabia
15.6.1.1. Saudi Arabia
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Type
15.6.1.1.1.
Therapeutic Procedure
15.6.1.1.2.
Diagnostic Procedure
15.6.1.2. Saudi Arabia
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Technique
15.6.1.2.1. Fluoroscopy-guided Technique 15.6.1.2.2. Ultrasound- guided
Technique
15.6.1.2.3. Computed Tomography- guided Technique
15.6.1.2.4. Others
15.6.1.3. Saudi Arabia
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
15.6.1.3.1.
Infections
15.6.1.3.1.1. Viral (including HIV) 15.6.1.3.1.2. Bacterial
15.6.1.3.1.3. Mycobacterial 15.6.1.3.1.4. Fungal and Protozoal
15.6.1.3.2. Infection of the Heart
or Pericardial Sac 15.6.1.3.3. Surgery or Invasive Heart
Procedures 15.6.1.3.4. Chest Trauma
15.6.1.3.5.
Malignancy
15.6.1.3.5.1.
Lung
15.6.1.3.5.2.
Breast
15.6.1.3.5.3.
Lymphoma
15.6.1.3.5.4. Melanoma
15.6.1.3.5.5.
Others
15.6.1.3.6. Immune
System Disease 15.6.1.3.7. Reactions to certain drugs 15.6.1.3.8. Radiation
15.6.1.3.9. Kidney (renal)
Failure 15.6.1.3.10. Others
15.6.1.4. Saudi Arabia
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and Forecasts, By Healthcare Setting
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Cardiac Centers
15.6.1.4.3. Others
15.6.2.
UAE
15.6.2.1. UAE Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
15.6.2.1.1.
Therapeutic Procedure
15.6.2.1.2.
Diagnostic Procedure
15.6.2.2. UAE Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
15.6.2.2.1.
Fluoroscopy-guided Technique
15.6.2.2.2.
Ultrasound- guided Technique
15.6.2.2.3. Computed Tomography- guided Technique
15.6.2.2.4. Others
15.6.2.3. UAE Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
15.6.2.3.1.
Infections
15.6.2.3.1.1. Viral (including HIV) 15.6.2.3.1.2. Bacterial
15.6.2.3.1.3. Mycobacterial 15.6.2.3.1.4. Fungal and Protozoal
15.6.2.3.2. Infection of the Heart
or Pericardial Sac 15.6.2.3.3. Surgery or Invasive Heart
Procedures 15.6.2.3.4. Chest Trauma
15.6.2.3.5.
Malignancy
15.6.2.3.5.1.
Lung
15.6.2.3.5.2.
Breast
15.6.2.3.5.3. Lymphoma
15.6.2.3.5.4.
Melanoma
15.6.2.3.5.5.
Others
15.6.2.3.6. Immune
System Disease 15.6.2.3.7. Reactions to certain drugs 15.6.2.3.8. Radiation
15.6.2.3.9. Kidney (renal)
Failure 15.6.2.3.10. Others
15.6.2.4. UAE Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Cardiac Centers
15.6.2.4.3. Others
15.6.3.
Egypt
15.6.3.1. Egypt Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
15.6.3.1.1.
Therapeutic Procedure
15.6.3.1.2.
Diagnostic Procedure
15.6.3.2. Egypt Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
15.6.3.2.1. Fluoroscopy-guided Technique 15.6.3.2.2. Ultrasound- guided
Technique
15.6.3.2.3. Computed Tomography- guided Technique
15.6.3.2.4. Others
15.6.3.3. Egypt Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
15.6.3.3.1.
Infections
15.6.3.3.1.1. Viral (including HIV) 15.6.3.3.1.2. Bacterial
15.6.3.3.1.3. Mycobacterial 15.6.3.3.1.4. Fungal and Protozoal
15.6.3.3.2. Infection of the Heart
or Pericardial Sac 15.6.3.3.3. Surgery or Invasive Heart
Procedures 15.6.3.3.4. Chest Trauma
15.6.3.3.5.
Malignancy
15.6.3.3.5.1. Lung
15.6.3.3.5.2.
Breast
15.6.3.3.5.3. Lymphoma
15.6.3.3.5.4.
Melanoma
15.6.3.3.5.5.
Others
15.6.3.3.6. Immune
System Disease 15.6.3.3.7. Reactions to certain drugs 15.6.3.3.8. Radiation
15.6.3.3.9. Kidney (renal)
Failure 15.6.3.3.10. Others
15.6.3.4. Egypt Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Cardiac Centers
15.6.3.4.3. Others
15.6.4.
Kuwait
15.6.4.1. Kuwait Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
15.6.4.1.1.
Therapeutic Procedure
15.6.4.1.2.
Diagnostic Procedure
15.6.4.2. Kuwait Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
15.6.4.2.1. Fluoroscopy-guided Technique 15.6.4.2.2. Ultrasound- guided
Technique
15.6.4.2.3. Computed Tomography- guided Technique
15.6.4.2.4. Others
15.6.4.3. Kuwait Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
15.6.4.3.1.
Infections
15.6.4.3.1.1. Viral (including HIV) 15.6.4.3.1.2. Bacterial
15.6.4.3.1.3. Mycobacterial 15.6.4.3.1.4. Fungal and Protozoal
15.6.4.3.2. Infection of the Heart
or Pericardial Sac 15.6.4.3.3. Surgery or Invasive Heart
Procedures 15.6.4.3.4. Chest Trauma
15.6.4.3.5.
Malignancy
15.6.4.3.5.1.
Lung
15.6.4.3.5.2.
Breast
15.6.4.3.5.3. Lymphoma
15.6.4.3.5.4.
Melanoma
15.6.4.3.5.5. Others
15.6.4.3.6. Immune
System Disease 15.6.4.3.7. Reactions to certain drugs 15.6.4.3.8. Radiation
15.6.4.3.9. Kidney (renal)
Failure 15.6.4.3.10. Others
15.6.4.4. Kuwait Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Cardiac Centers
15.6.4.4.3. Others
15.6.5.
South Africa
15.6.5.1. South Africa Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.1.1.
Therapeutic Procedure
15.6.5.1.2.
Diagnostic Procedure
15.6.5.2. South Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
15.6.5.2.1. Fluoroscopy-guided Technique 15.6.5.2.2. Ultrasound- guided
Technique
15.6.5.2.3. Computed Tomography- guided Technique
15.6.5.2.4. Others
15.6.5.3. South Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.6.5.3.1.
Infections
15.6.5.3.1.1. Viral (including HIV) 15.6.5.3.1.2. Bacterial
15.6.5.3.1.3. Mycobacterial
15.6.5.3.1.4. Fungal
and Protozoal 15.6.5.3.2. Infection of the Heart or Pericardial Sac 15.6.5.3.3. Surgery or Invasive Heart Procedures 15.6.5.3.4.
Chest Trauma
15.6.5.3.5.
Malignancy
15.6.5.3.5.1. Lung
15.6.5.3.5.2.
Breast
15.6.5.3.5.3.
Lymphoma
15.6.5.3.5.4.
Melanoma
15.6.5.3.5.5.
Others
15.6.5.3.6. Immune
System Disease 15.6.5.3.7. Reactions to certain drugs 15.6.5.3.8. Radiation
15.6.5.3.9. Kidney (renal)
Failure 15.6.5.3.10. Others
15.6.5.4. South Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Healthcare Setting
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Cardiac Centers
15.6.5.4.3. Others
15.6.6.
Rest of Middle
East & Africa
15.6.6.1. Rest of Middle East & Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By
Type
15.6.6.1.1.
Therapeutic Procedure
15.6.6.1.2.
Diagnostic Procedure
15.6.6.2. Rest of Middle East & Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By
Technique
15.6.6.2.1. Fluoroscopy-guided Technique 15.6.6.2.2. Ultrasound- guided
Technique
15.6.6.2.3. Computed Tomography- guided Technique
15.6.6.2.4. Others
15.6.6.3. Rest of Middle East & Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.6.6.3.1.
Infections
15.6.6.3.1.1. Viral (including HIV) 15.6.6.3.1.2. Bacterial
15.6.6.3.1.3. Mycobacterial 15.6.6.3.1.4. Fungal and Protozoal
15.6.6.3.2. Infection of the Heart
or Pericardial Sac 15.6.6.3.3. Surgery or Invasive Heart
Procedures
15.6.6.3.4.
Chest Trauma
15.6.6.3.5.
Malignancy
15.6.6.3.5.1. Lung
15.6.6.3.5.2.
Breast
15.6.6.3.5.3.
Lymphoma
15.6.6.3.5.4.
Melanoma
15.6.6.3.5.5. Others
15.6.6.3.6. Immune
System Disease 15.6.6.3.7. Reactions to certain drugs 15.6.6.3.8. Radiation
15.6.6.3.9. Kidney (renal)
Failure 15.6.6.3.10. Others
15.6.6.4. Rest of Middle East & Africa
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By
Healthcare Setting
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Cardiac Centers
15.6.6.4.3. Others
15.7. Key Segment
for Channeling Investments
15.7.1.
By Country
15.7.2.
By Type
15.7.3.
By Technique
15.7.4.
By Disease Indication
15.7.5.
By Healthcare Setting
16. Latin America Pericardiocentesis Procedures Market Analysis
and Forecasts, 2023 – 2031
16.1. Overview
16.1.1.
Latin America Pericardiocentesis Procedures Market Revenue
(US$ Mn)
16.2.
Latin America Pericardiocentesis
Procedures Market Revenue (US$ Mn)
and Forecasts, By Type
16.2.1.
Therapeutic Procedure
16.2.2.
Diagnostic Procedure
16.3.
Latin America Pericardiocentesis
Procedures Market Revenue (US$ Mn)
and Forecasts, By Technique
16.3.1.
Fluoroscopy-guided Technique
16.3.2.
Ultrasound- guided Technique
16.3.3.
Computed Tomography- guided
Technique
16.3.4.
Others
16.4.
Latin America Pericardiocentesis
Procedures Market Revenue (US$ Mn)
and Forecasts, By Disease Indication
16.4.1.
Infections
16.4.1.1.
Viral (including HIV)
16.4.1.2.
Bacterial
16.4.1.3.
Mycobacterial
16.4.1.4.
Fungal and Protozoal
16.4.2.
Infection of the Heart or Pericardial Sac
16.4.3.
Surgery or Invasive
Heart Procedures
16.4.4.
Chest Trauma
16.4.5.
Malignancy
16.4.5.1.
Lung
16.4.5.2.
Breast
16.4.5.3.
Lymphoma
16.4.5.4.
Melanoma
16.4.5.5.
Others
16.4.6.
Immune System Disease
16.4.7.
Reactions to certain
drugs
16.4.8.
Radiation
16.4.9.
Kidney (renal) Failure
16.4.10.
Others
16.5.
Latin America Pericardiocentesis
Procedures Market Revenue (US$ Mn)
and Forecasts, By Healthcare Setting
16.5.1.
Hospitals and Clinics
16.5.2.
Cardiac Centers
16.5.3.
Others
16.6.
Latin America Pericardiocentesis
Procedures Market Revenue (US$ Mn)
and Forecasts, By Country
16.6.1.
Brazil
16.6.1.1. Brazil Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
16.6.1.1.1.
Therapeutic Procedure
16.6.1.1.2.
Diagnostic Procedure
16.6.1.2. Brazil Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
16.6.1.2.1. Fluoroscopy-guided Technique 16.6.1.2.2. Ultrasound- guided
Technique
16.6.1.2.3. Computed Tomography- guided Technique
16.6.1.2.4. Others
16.6.1.3. Brazil Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
16.6.1.3.1.
Infections
16.6.1.3.1.1. Viral (including HIV) 16.6.1.3.1.2. Bacterial
16.6.1.3.1.3. Mycobacterial 16.6.1.3.1.4. Fungal and Protozoal
16.6.1.3.2. Infection of the Heart
or Pericardial Sac 16.6.1.3.3. Surgery or Invasive Heart
Procedures 16.6.1.3.4. Chest Trauma
16.6.1.3.5.
Malignancy
16.6.1.3.5.1.
Lung
16.6.1.3.5.2.
Breast
16.6.1.3.5.3. Lymphoma
16.6.1.3.5.4.
Melanoma
16.6.1.3.5.5.
Others
16.6.1.3.6. Immune
System Disease 16.6.1.3.7. Reactions to certain drugs 16.6.1.3.8. Radiation
16.6.1.3.9. Kidney (renal)
Failure 16.6.1.3.10. Others
16.6.1.4. Brazil Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Cardiac Centers
16.6.1.4.3. Others
16.6.2.
Argentina
16.6.2.1. Argentina Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Type
16.6.2.1.1.
Therapeutic Procedure
16.6.2.1.2.
Diagnostic Procedure
16.6.2.2. Argentina Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Technique
16.6.2.2.1. Fluoroscopy-guided Technique 16.6.2.2.2. Ultrasound- guided
Technique
16.6.2.2.3. Computed Tomography- guided Technique
16.6.2.2.4. Others
16.6.2.3. Argentina Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Disease Indication
16.6.2.3.1.
Infections
16.6.2.3.1.1. Viral (including HIV) 16.6.2.3.1.2. Bacterial
16.6.2.3.1.3. Mycobacterial 16.6.2.3.1.4. Fungal and Protozoal
16.6.2.3.2.
Infection of the Heart or Pericardial Sac
16.6.2.3.3. Surgery or Invasive Heart
Procedures 16.6.2.3.4. Chest Trauma
16.6.2.3.5.
Malignancy
16.6.2.3.5.1. Lung
16.6.2.3.5.2.
Breast
16.6.2.3.5.3.
Lymphoma
16.6.2.3.5.4.
Melanoma
16.6.2.3.5.5.
Others
16.6.2.3.6. Immune
System Disease 16.6.2.3.7. Reactions to certain drugs 16.6.2.3.8. Radiation
16.6.2.3.9. Kidney (renal)
Failure 16.6.2.3.10. Others
16.6.2.4. Argentina Pericardiocentesis Procedures Market Revenue
(US$ Mn) and Forecasts, By Healthcare Setting
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Cardiac Centers
16.6.2.4.3. Others
16.6.3.
Rest of Latin America
16.6.3.1. Rest of Latin America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and
Forecasts, By Type
16.6.3.1.1.
Therapeutic Procedure
16.6.3.1.2.
Diagnostic Procedure
16.6.3.2. Rest of Latin America
Pericardiocentesis Procedures Market Revenue (US$ Mn) and Forecasts, By Technique
16.6.3.2.1. Fluoroscopy-guided Technique 16.6.3.2.2. Ultrasound- guided
Technique
16.6.3.2.3. Computed Tomography- guided Technique
16.6.3.2.4. Others
16.6.3.3. Rest of Latin America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and
Forecasts, By Disease Indication
16.6.3.3.1.
Infections
16.6.3.3.1.1. Viral (including HIV) 16.6.3.3.1.2. Bacterial
16.6.3.3.1.3. Mycobacterial 16.6.3.3.1.4. Fungal and Protozoal
16.6.3.3.2. Infection of the Heart
or Pericardial Sac 16.6.3.3.3. Surgery or Invasive Heart
Procedures 16.6.3.3.4. Chest Trauma
16.6.3.3.5.
Malignancy
16.6.3.3.5.1. Lung
16.6.3.3.5.2.
Breast
16.6.3.3.5.3. Lymphoma
16.6.3.3.5.4.
Melanoma
16.6.3.3.5.5.
Others
16.6.3.3.6. Immune
System Disease 16.6.3.3.7. Reactions to certain drugs 16.6.3.3.8. Radiation
16.6.3.3.9. Kidney (renal)
Failure 16.6.3.3.10. Others
16.6.3.4. Rest of Latin America
Pericardiocentesis Procedures Market
Revenue (US$ Mn) and
Forecasts, By Healthcare Setting
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Cardiac Centers
16.6.3.4.3. Others
16.7. Key Segment
for Channeling Investments
16.7.1.
By Country
16.7.2.
By Type
16.7.3.
By Technique
16.7.4.
By Disease Indication
16.7.5.
By Healthcare Setting
17. Competitive Benchmarking
17.1. Market Share Analysis, 2022
17.2. Global Presence
and Growth Strategies
17.2.1.
Mergers and Acquisitions
17.2.2.
Product Launches
17.2.3.
Investments Trends
17.2.4.
R&D Initiatives
18. Player Profiles
18.1. Apollo Hospitals Enterprise Ltd
18.1.1.
Company Details
18.1.2.
Company Overview
18.1.3.
Product Offerings
18.1.4.
Key Developments
18.1.5.
Financial Analysis
18.1.6.
SWOT Analysis
18.1.7.
Business Strategies
18.2. Cleveland Clinic
18.2.1.
Company Details
18.2.2.
Company Overview
18.2.3.
Product Offerings
18.2.4.
Key Developments
18.2.5.
Financial Analysis
18.2.6.
SWOT Analysis
18.2.7.
Business Strategies
18.3. The Johns Hopkins Hospital
18.3.1.
Company Details
18.3.2.
Company Overview
18.3.3.
Product Offerings
18.3.4.
Key Developments
18.3.5.
Financial Analysis
18.3.6.
SWOT Analysis
18.3.7.
Business Strategies
18.4. The Mesothelioma Center
18.4.1.
Company Details
18.4.2.
Company Overview
18.4.3.
Product Offerings
18.4.4.
Key Developments
18.4.5.
Financial Analysis
18.4.6.
SWOT Analysis
18.4.7.
Business Strategies
18.5. The Ohio State University Wexner Medical Center
18.5.1.
Company Details
18.5.2.
Company Overview
18.5.3.
Product Offerings
18.5.4.
Key Developments
18.5.5.
Financial Analysis
18.5.6.
SWOT Analysis
18.5.7.
Business Strategies
18.6. University Hospitals
18.6.1.
Company Details
18.6.2.
Company Overview
18.6.3.
Product Offerings
18.6.4.
Key Developments
18.6.5.
Financial Analysis
18.6.6.
SWOT Analysis
18.6.7.
Business Strategies
18.7. Weill Cornell
Medicine
18.7.1.
Company Details
18.7.2.
Company Overview
18.7.3.
Product Offerings
18.7.4.
Key Developments
18.7.5.
Financial Analysis
18.7.6.
SWOT Analysis
18.7.7.
Business Strategies
18.8. Winchester Hospital
18.8.1.
Company Details
18.8.2.
Company Overview
18.8.3.
Product Offerings
18.8.4.
Key Developments
18.8.5.
Financial Analysis
18.8.6.
SWOT Analysis
18.8.7.
Business Strategies
18.9. Other Market Participants
19. Key Findings
Note: This ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
